These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

238 related items for PubMed ID: 10226579

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Biological activity of the multitargeted antifolate, MTA (LY231514), in human cell lines with different resistance mechanisms to antifolate drugs.
    Schultz RM, Chen VJ, Bewley JR, Roberts EF, Shih C, Dempsey JA.
    Semin Oncol; 1999 Apr; 26(2 Suppl 6):68-73. PubMed ID: 10598558
    [Abstract] [Full Text] [Related]

  • 3. Prevention of thymidine and hypoxanthine rescue from MTA (LY231514) growth inhibition by dipyridamole in human lung cancer cell lines.
    Smith PG, Marshman E, Calvert AH, Newell DR, Curtin NJ.
    Semin Oncol; 1999 Apr; 26(2 Suppl 6):63-7. PubMed ID: 10598557
    [Abstract] [Full Text] [Related]

  • 4. Modulation of both endogenous folates and thymidine enhance the therapeutic efficacy of thymidylate synthase inhibitors.
    van der Wilt CL, Backus HH, Smid K, Comijn L, Veerman G, Wouters D, Voorn DA, Priest DG, Bunni MA, Mitchell F, Jackman AL, Jansen G, Peters GJ.
    Cancer Res; 2001 May 01; 61(9):3675-81. PubMed ID: 11325838
    [Abstract] [Full Text] [Related]

  • 5. Role of folic acid in modulating the toxicity and efficacy of the multitargeted antifolate, LY231514.
    Worzalla JF, Shih C, Schultz RM.
    Anticancer Res; 1998 May 01; 18(5A):3235-9. PubMed ID: 9858888
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Thymidylate synthase level as the main predictive parameter for sensitivity to 5-fluorouracil, but not for folate-based thymidylate synthase inhibitors, in 13 nonselected colon cancer cell lines.
    van Triest B, Pinedo HM, van Hensbergen Y, Smid K, Telleman F, Schoenmakers PS, van der Wilt CL, van Laar JA, Noordhuis P, Jansen G, Peters GJ.
    Clin Cancer Res; 1999 Mar 01; 5(3):643-54. PubMed ID: 10100718
    [Abstract] [Full Text] [Related]

  • 8. Cytotoxicity of antifolate inhibitors of thymidylate and purine synthesis to WiDr colonic carcinoma cells.
    Smith SG, Lehman NL, Moran RG.
    Cancer Res; 1993 Dec 01; 53(23):5697-706. PubMed ID: 8242626
    [Abstract] [Full Text] [Related]

  • 9. Antitumor activity of ZD1694 (tomudex) against human head and neck cancer in nude mouse models: role of dosing schedule and plasma thymidine.
    Cao S, McGuire JJ, Rustum YM.
    Clin Cancer Res; 1999 Jul 01; 5(7):1925-34. PubMed ID: 10430100
    [Abstract] [Full Text] [Related]

  • 10. Dipyridamole potentiates the in vitro activity of MTA (LY231514) by inhibition of thymidine transport.
    Smith PG, Marshman E, Newell DR, Curtin NJ.
    Br J Cancer; 2000 Feb 01; 82(4):924-30. PubMed ID: 10732767
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Determinants of activity of the antifolate thymidylate synthase inhibitors Tomudex (ZD1694) and GW1843U89 against mono- and multilayered colon cancer cell lines under folate-restricted conditions.
    Peters GJ, Smitskamp-Wilms E, Smid K, Pinedo HM, Jansen G.
    Cancer Res; 1999 Nov 01; 59(21):5529-35. PubMed ID: 10554030
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Enzyme inhibition, polyglutamation, and the effect of LY231514 (MTA) on purine biosynthesis.
    Mendelsohn LG, Shih C, Chen VJ, Habeck LL, Gates SB, Shackelford KA.
    Semin Oncol; 1999 Apr 01; 26(2 Suppl 6):42-7. PubMed ID: 10598554
    [Abstract] [Full Text] [Related]

  • 15. Increased thymidylate synthase in L1210 cells possessing acquired resistance to N10-propargyl-5,8-dideazafolic acid (CB3717): development, characterization, and cross-resistance studies.
    Jackman AL, Alison DL, Calvert AH, Harrap KR.
    Cancer Res; 1986 Jun 01; 46(6):2810-5. PubMed ID: 2938731
    [Abstract] [Full Text] [Related]

  • 16. Loss of reduced folate carrier function and folate depletion result in enhanced pemetrexed inhibition of purine synthesis.
    Zhao R, Zhang S, Hanscom M, Chattopadhyay S, Goldman ID.
    Clin Cancer Res; 2005 Feb 01; 11(3):1294-301. PubMed ID: 15709201
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Multiple folate enzyme inhibition: mechanism of a novel pyrrolopyrimidine-based antifolate LY231514 (MTA).
    Shih C, Habeck LL, Mendelsohn LG, Chen VJ, Schultz RM.
    Adv Enzyme Regul; 1998 Feb 01; 38():135-52. PubMed ID: 9762351
    [Abstract] [Full Text] [Related]

  • 20. Antifolate pseudo-resistance due to elevated levels of thymidine and hypoxanthine in a commercial serum preparation.
    Simon M, Blatter J, Granzow C.
    Anticancer Res; 2007 Feb 01; 27(2):769-73. PubMed ID: 17465201
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.